Browse the evidence

Internet search responses were more heterogeneous and often commercially biased.

Practitioners should critically evaluate internet sources for GLP1RA information due to potential bias.

Reoperation odds among ACDF/GLP-1RA patients were significantly reduced at 12 months (4% vs. 6%; OR=0.689) and 24 months postoperatively (5% vs. 7%; OR=0.692).

GLP-1RAs may help reduce the need for reoperation in ACDF patients.

GLP-1RA use was associated with significantly reduced odds of pseudarthrosis by more than 20% and reoperation by more than 30% at 24 months following ACDF.

GLP-1RAs may significantly improve postoperative outcomes in ACDF patients.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events and non-fatal stroke in patients with type 2 diabetes mellitus.

Practitioners should consider GLP-1RAs as a therapeutic option for reducing cardiovascular risks in patients with type 2 diabetes.

GLP-1RAs provide direct neurovascular protection by stabilizing the blood-brain barrier and modulating neuroinflammation.

GLP-1RAs may be beneficial in protecting brain health and reducing stroke risk.

Meta-regression showed no significant effect modification by age, body mass index, HbA1c, follow-up duration, or sodium-glucose co-transporter 2 inhibitors use.

The effectiveness of semaglutide is consistent regardless of these common patient characteristics.

Several classes of medications have been explored to target different pathways and receptors to preserve lean body mass during weight loss.

Practitioners may consider pharmacological options to help preserve muscle mass during weight loss.

Excess visceral abdominal fat (EVAF) can occur in people living with HIV-1 even with normal or mildly elevated body mass index (BMI).

Healthcare providers should assess visceral fat in PLWH regardless of BMI.

Over half (60%) of participants with a BMI indicating obesity had no clinical diagnosis of obesity in their EHRs.

Clinicians should be aware that a significant number of patients with obesity may not be diagnosed, potentially leading to untreated health issues.

Men, and particularly NH-Asian men, may be at heightened risk of underdiagnosis of obesity.

Awareness of potential underdiagnosis in specific male populations can improve obesity management strategies.

GLP-1RAs are being studied in clinical settings not previously examined in original trials.

Practitioners should stay informed about the evolving applications of GLP-1RAs in clinical practice.

Patients who have undergone significant weight loss are at increased risk of thromboembolic events, particularly after body contouring procedures.

Practitioners should monitor thromboembolic risk in post-weight-loss patients undergoing surgery.

Naltrexone/bupropion may benefit sexual desire through mood improvement.

Practitioners might consider Naltrexone/bupropion for patients seeking improvements in sexual desire linked to mood.

DPP-4 inhibitors offer stroke prevention and cognitive advantages, particularly in patients with renal impairment.

DPP-4 inhibitors may be considered for patients at risk of stroke and cognitive decline.

The findings suggest potential neurobehavioral benefits associated with incretin-based therapies (IBTs) in a high-risk population.

These findings may guide clinicians in selecting appropriate treatments for patients at risk of AUD post-surgery.

Recent progress in glucose-responsive systems enables real-time, glucose-triggered therapeutic activation.

This technology could lead to more effective and responsive diabetes treatments.

Hemoglobin A1c decreased across all groups but remained consistently higher in NHB and H compared with NHW at 24 months.

Monitoring of Hemoglobin A1c levels should be tailored based on race and ethnicity post-surgery.

NHB participants reported higher perceived discrimination, sleep disturbance, and perceived stress than H and NHW participants at all time points.

Addressing psychosocial factors is crucial for improving surgical outcomes in NHB patients.

GLP-1RA therapy was associated with a lower risk of all-cause mortality in nondiabetic patients with PAD (HR: 0.40; 95% CI: 0.35–0.46; p < 0.001).

GLP-1RAs may help reduce overall mortality in patients with PAD who do not have diabetes.

GLP-1RA therapy was associated with a lower risk of major adverse limb events (MALE) in nondiabetic patients with PAD (HR: 0.22; 95% CI: 0.17–0.28; p < 0.001).

GLP-1RAs may reduce the risk of serious limb complications in patients with PAD who do not have diabetes.

There may be a potential causal relationship between tirzepatide and vitreous hemorrhage in nondiabetic patients.

Caution is advised when prescribing tirzepatide, especially in nondiabetic patients.

MPDA@TZP increased the retention time of TZP in the iWAT of mice and had a more dramatic effect on weight loss and improvement in plasma lipid profiles compared to TZP alone in DIO mice.

Encapsulating tirzepatide may enhance its effectiveness for weight loss in specific adipose tissues.

Emerging clinical trials support the potential of GLP-1 receptor agonists in reversing cancer risk.

Practitioners should stay updated on clinical trial results regarding GLP-1 agonists and cancer risk.

Dietary supplements are generally safe, but their regulation is less stringent than for medicines.

Practitioners should ensure patients are aware of the regulatory status of dietary supplements.